Combined Therapy of Hypertensive Nephropathy with Breviscapine Injection and Antihypertensive Drugs: A Systematic Review and a Meta-Analysis
المؤلفون المشاركون
Fang, Zhuyuan
Wu, Lihua
Liu, Ming
المصدر
Evidence-Based Complementary and Alternative Medicine
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-17، 17ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-12-20
دولة النشر
مصر
عدد الصفحات
17
التخصصات الرئيسية
الملخص EN
Objective.
To evaluate the beneficial and adverse effects of breviscapine injection in combination with antihypertensive drugs for treating hypertensive nephropathy in clinical practice.
Methods.
We searched PubMed, the Cochrane Library, Embase, CNKI, Sino Med, VIP, and Wanfang Data for relevant literature.
The timeframe of retrieval was set from the founding date of each database to September 28, 2018.
Results.
Fourteen papers were included in this study.
The quality of all the studies included was determined to be low.
All studies were conducted with Chinese populations.
Meta-analysis showed that, compared with single-use antihypertensive drugs, using breviscapine injection in combination with antihypertensive drugs to treat hypertensive nephropathy can reduce serum creatinine (Scr) [WMD = –35.16, 95% CI(–50.01, –20.31), P ≤ 0.001], blood urea nitrogen (BUN) [WMD = –2.00, 95% CI(–3.07, –0.94), P ≤ 0.001], 24-hour urinary total protein (24 h UTP) [WMD = –0.04, 95% CI(–0.05, –0.02), P ≤ 0.001], and the beta-2-microglobulin (B2M) [WMD = –0.09, 95% CI(–0.11, –0.07), P ≤ 0.001], improve creatinine clearance rate (Ccr) [WMD = 7.84, 95% CI(5.20, 10.49), P ≤ 0.001], and increase the clinical efficacy [RR = 1.27, 95% CI(1.05, 1.53), P = 0.014], but does not lower systolic blood pressure (SBP) [WMD = –1.02, 95% CI(–2.88, 0.84), P = 0.281].
There was no significant difference in adverse events between experimental groups and control groups.
Conclusion.
Breviscapine injection in combination with antihypertensive drugs can improve clinical efficacy and Ccr and reduce Scr, BUN, 24 h UTP, and B2M in patients with hypertensive nephropathy.
The present meta-analysis indicated that breviscapine injection can serve as a renal protective effect to patients with hypertensive nephropathy.
However, the evidence of methodological quality and sample sizes is weak, and thus, further standardized research is required.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Wu, Lihua& Liu, Ming& Fang, Zhuyuan. 2018. Combined Therapy of Hypertensive Nephropathy with Breviscapine Injection and Antihypertensive Drugs: A Systematic Review and a Meta-Analysis. Evidence-Based Complementary and Alternative Medicine،Vol. 2018, no. 2018, pp.1-17.
https://search.emarefa.net/detail/BIM-1154719
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Wu, Lihua…[et al.]. Combined Therapy of Hypertensive Nephropathy with Breviscapine Injection and Antihypertensive Drugs: A Systematic Review and a Meta-Analysis. Evidence-Based Complementary and Alternative Medicine No. 2018 (2018), pp.1-17.
https://search.emarefa.net/detail/BIM-1154719
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Wu, Lihua& Liu, Ming& Fang, Zhuyuan. Combined Therapy of Hypertensive Nephropathy with Breviscapine Injection and Antihypertensive Drugs: A Systematic Review and a Meta-Analysis. Evidence-Based Complementary and Alternative Medicine. 2018. Vol. 2018, no. 2018, pp.1-17.
https://search.emarefa.net/detail/BIM-1154719
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1154719
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر